Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: tgn-1412, lulizumab pegol | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 20 Parkinson's papers of 13,931 | 0.60 |
| pathways Reactome | 7 pathways; mostly growth signalling | 0.60 |
No case: the score is under the bar. Receipt 6762
Sealed predictions
- CD28 in dopamine neurons, braak-0.21 (p 0.586) → +0.35 (p 0.354)receipt 6770
Swarm cases
receipt 6770: CD28 in dopamine neurons, braak
- power
- full sample -0.01 (p 0.969, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.07 (p 0.787, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.12 (p 0.640, n 18). could be the mix.
- skeptic
- leave-one-out range -0.13 to +0.12, sign flips 10; without severely affected donors -0.01 (p 0.969, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD28 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts